Core Insights - The presentation features the Viking team, including the CEO and CFO, discussing the current landscape in cardiometabolic obesity, highlighting its significance and the opportunities within the industry [1]. Group 1: Company Overview - Viking is actively engaging with the biopharma sector, particularly focusing on cardiometabolic obesity, which is a growing area of interest [1]. - The company is positioned to compete with and potentially partner with large-cap names in the biopharma industry [2]. Group 2: Presentation Format - The session includes a presentation followed by a Q&A segment, utilizing the Pigeonhole app for audience interaction [3].

Summary of the Conference Call Transcript Industry Overview - **Industry**: China Healthcare - **Key Companies Mentioned**: Akeso, Innovent, Hansoh, BeOne, Simcere, Duality Bio, Leads Bio, GenFleet, CSPC, Sino Biopharm, Mindray Core Insights and Arguments 1. **Investor Focus Areas**: Investors are concentrating on potential licensing-out opportunities, risks associated with potential Executive Orders from the US Administration, and current valuations of biopharma companies [2][3] 2. **Investor Sentiment**: There is a notable interest in Akeso for potential buying opportunities, while BeOne and Simcere are perceived as undervalued [2] 3. **Emerging Companies**: Newer companies like Duality Bio, Leads Bio, and GenFleet are attracting strong interest from investors [2] 4. **Generalist Investors' Participation**: Generalist investors have increased their participation in the healthcare sector year-to-date, with many being equal or overweight relative to the MSCI sector percentage [3] 5. **Caution Among Specialists**: Specialists are becoming more cautious regarding companies driven by business development expectations, particularly CSPC and Sino Biopharm, due to uncertainties around US approvals [4] 6. **Valuation Concerns**: Generalist investors are turning conservative on companies with high business development valuation contributions due to potential restrictions from US Executive Orders [3] 7. **Performance of Core Holdings**: Hengrui and Hansoh are noted for their strong performance as core holdings due to their consistent track record and R&D capabilities [3] Risks and Challenges 1. **Healthcare Industry Risks**: Key risks identified for China's healthcare industry include: - Worse-than-expected price cuts from GPO programs - Intensified competition - Lower-than-expected innovative drug prices negotiated for NRDLs - Slower-than-expected consumption recovery in China - Stricter-than-expected regulatory announcements and implementations - Rising geopolitical tensions affecting operations [6] Additional Insights 1. **Market Dynamics**: Investors are showing interest in relatively inexpensive valuations of CXO and medtech names, looking for potential growth acceleration or recovery [2] 2. **Profit-Taking**: Generalist investors are considering profit-taking on certain names due to difficulties in identifying alpha opportunities in crowded therapeutic areas [3] 3. **IPO Interest**: There is interest in new IPO listings, particularly GenFleet, as investors seek opportunities outside of established names [4] Conclusion The conference call highlighted a cautious yet opportunistic sentiment among investors in the China healthcare sector, with a focus on emerging companies and potential risks stemming from regulatory changes and market dynamics. The overall investor landscape is shifting, with generalist investors becoming more selective and specialists expressing caution regarding business development-driven companies.

Core Insights - The current market presents a challenge for investors seeking safe places to allocate new capital, as the S&P 500 is experiencing record highs and significant rallies [1] - There are still opportunities to find relatively inexpensive stocks with above-average growth potential, particularly within the S&P 500 [2] Stock Selection - A screen identified 104 S&P 500 stocks with above-average growth and below-average price multiples, narrowing down to 86 after excluding energy and materials sectors [3][4] - T-Mobile is highlighted for its expected 19.4% earnings growth next year, trading at just over 18 times next year's earnings [4] - Royal Caribbean and Expedia are noted as strong travel stocks, with Expedia projected to grow earnings by 18% next year while trading at 13 times earnings, significantly cheaper than Booking Holdings [5] - Dollar Tree is identified as a consumer staples stock with a 15% growth rate, trading at less than 15 times next year's earnings, making it a favorable option [6] Financial Sector Opportunities - The financial sector is experiencing favorable conditions, with 34 of the 86 identified stocks coming from this sector [7] - Capital One Financial is projected to have nearly 14% earnings growth next year, trading at roughly 11 times next year's earnings [8] - American Express is expected to grow earnings by 12.6% next year, trading at less than 20 times earnings, which is cheaper than the overall S&P [9] - Citigroup is highlighted for its strong recovery under CEO Jane Fraser, with expected growth of 28% next year while trading at just 10.5 times earnings [10] - Keycorp, a regional bank, is expected to grow at 22% next year, trading at just under 11 times next year's earnings [11] Other Notable Stocks - Charles Schwab is recognized as a strong retail brokerage, while Apollo is noted for its leadership in private equity and private credit with projected earnings growth of 19% [12][13] - Insight, a biopharma company, stands out in the healthcare sector with expected earnings growth of 19% and trading at just under 12 times next year's earnings [14] - Caterpillar is noted for its strong performance, with an expected 18% earnings growth and trading at 22 times next year's earnings [15] - Dell Technologies is mentioned as a core player in AI infrastructure, while BXP, a real estate company, has rebounded after trimming its dividend to focus on growth projects [18][19] - Energy, a utility company, is highlighted for its growth potential due to infrastructure projects, including a $10 billion data center by Meta [20]

Group 1: Company Performance - Broyhill Asset Management reported a 3.7% net appreciation in its Broyhill Partners fund for Q2 2025, which is lower than the MSCI All Country World Index's return of 11.7% for the same period [1] - Avantor, Inc. (NYSE:AVTR) experienced a 17% decline in its stock price during Q2 2025, continuing its downward trend into Q3 after missing earnings and cutting guidance [3] - Avantor, Inc. reported flat revenue of $1.68 billion year-over-year on an organic basis for Q2 2025 [4] Group 2: Market Context and Competitors - The competitive environment in the biopharma and healthcare sectors has intensified due to budget cuts in academic research and commercial pharmaceuticals, leading to market share losses for Avantor [3] - Following the decline in Avantor's stock, Broyhill Asset Management shifted some exposure to competitor Thermo Fisher Scientific while evaluating market dynamics [3] Group 3: Investor Sentiment and Future Outlook - An activist investor has acquired a significant stake in Avantor and is pushing for a board overhaul or strategic review, indicating potential changes in governance [3] - Despite recent challenges, Broyhill Asset Management believes Avantor represents significant value at current levels and anticipates a positive shift with new board perspectives [3] - The number of hedge funds holding Avantor increased from 38 to 49 in Q2 2025, suggesting growing interest among institutional investors [4]

>> Interesting stuff. Angelica. Thank you.We will be watching that and watching shares of those companies and those commercials. Very catchy. Well, speaking of healthcare, J&J is on your radar today for the best stocks in the market.Josh. >> Yes, I almost said with Jardiance it's easy to say I'm lowering my a-1c, but I didn't want to get CNBC in trouble. I don't know if they're a sponsor.All right J&J. Okay. This is a this is a great setup for me to explain a really important concept that transcends the J&J ...

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $14 million, rebounding from $12.4 million in Q4 of fiscal 2025, indicating a recovery from previous softness [3][7] - Year-over-year revenue comparison appears flat, but the current quarter is viewed as a return to stability and the start of renewed momentum [8] - GAAP loss from operations was $0.5 million compared to income of $1.3 million in the same quarter last year, with adjusted EBITDA slightly positive at $60,000 [8][9] Business Line Data and Key Metrics Changes - Research services contributed $13.7 million to the total revenue, while the data business provided the remaining amount [7] - Gross margin decreased to 43% from 50% year-over-year, primarily due to increased outsourced lab service costs [8][9] - Operating expenses rose to $6 million, with intentional increases in R&D and sales and marketing to support the data business [9] Market Data and Key Metrics Changes - Customer cancellations have decreased, and bookings to revenue conversion has improved, indicating stronger customer relationships [4] - The macro environment remains challenging, but there are signs of improvement in biotech funding and R&D budgets [3][4] Company Strategy and Development Direction - The company aims to drive value opportunities in Corellia and its data business while expanding its core TOS platform [3][4] - The focus is on integrating radiopharmaceutical services to enhance customer offerings and improve gross margins [4][5] - The company is optimistic about the long-term potential of AI and machine learning in drug discovery [5] Management's Comments on Operating Environment and Future Outlook - Management expresses cautious optimism regarding the investment landscape, noting improvements in budget constraints [20][21] - The company anticipates sequential revenue growth and margin expansion as operations improve [11] - There is confidence in the ability to execute and deliver shareholder value, supported by a strong balance sheet and no debt [11] Other Important Information - The company ended Q1 with $10.3 million in cash, up $0.5 million from year-end, and expects to remain cash neutral in Q2 [10][11] - Management emphasizes the importance of investments in R&D and sales and marketing for future growth [9] Q&A Session Summary Question: Changes in data licensing business strategy - Management confirmed no changes in strategy for the data licensing business, with early wins and customer engagement being encouraging [14] Question: Size of the opportunity in the data business - Management stated it is too early to predict the exact size and success of the data opportunity, but there is potential and interest [15] Question: Deal structuring for Corellia - Management is looking for external partners and funding to support Corellia's advancement, with compelling data emerging from the platform [16] Question: Broader investment landscape - Management described the environment as tough but cautiously optimistic about improvements in market conditions [20] Question: Revenue expectations for Q2 - Management anticipates revenue will increase on a quarterly basis but did not provide specific guidance on numbers [27]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $14 million, rebounding from $12.4 million in Q4, indicating a recovery from previous softness [3][7] - Year-over-year revenue comparison appears flat, but the company views this quarter as a return to stability and the start of renewed momentum [8] - GAAP loss from operations was $0.5 million compared to income of $1.3 million in the same quarter last year, with adjusted EBITDA slightly positive at $60,000 [8][11] Business Line Data and Key Metrics Changes - Research services contributed $13.7 million to revenue, while the data business provided the remainder [7] - Gross margin decreased to 43% from 50% year-over-year, primarily due to increased outsourced lab service costs [8] - Operating expenses rose to $6 million, with intentional increases in R&D and sales and marketing to support the data business [9] Market Data and Key Metrics Changes - Customer cancellations are down, and bookings to revenue conversion has increased, indicating improved customer relationships [4] - The macro environment remains challenging, but there are signs of improvement in biotech funding and R&D budgets [3][20] Company Strategy and Development Direction - The company is focused on driving value opportunities in Corellia and its data business while expanding its TOS platform [3] - The radiopharmaceutical services platform is being enhanced with new infrastructure and capabilities, aiming to reduce costs and improve gross margins [4] - The data platform is gaining momentum, with three consecutive quarters of data sales since the first licensing deal [4] Management Comments on Operating Environment and Future Outlook - Management expresses cautious optimism about improving market conditions, although they do not expect a rapid recovery [20] - The company anticipates sequential revenue growth and margin expansion as they bring more work in-house [11] - There is confidence in the long-term potential of the data business and Corellia, despite current funding challenges in biotech [5][11] Other Important Information - The company ended Q1 with $10.3 million in cash, remaining debt-free, which provides flexibility for future investments [10] - Management plans to continue updating stakeholders on progress in the next earnings call scheduled for mid-December [32] Q&A Session Summary Question: Any changes in the strategy on the data licensing business? - Management confirmed there are no changes to the strategy, emphasizing early wins and potential in the data business [14] Question: How would you characterize the size of the opportunity in the data business? - Management stated it is still early to predict the exact size and success of the opportunity, but there is significant interest [15] Question: What frameworks are being considered for structuring deals with Corellia? - Management indicated they are looking for external partners and funding to support Corellia's advancement [16] Question: Can you provide insights on the broader investment landscape? - Management noted it remains a tough environment but sees signs of improvement and feels well-positioned to capitalize on opportunities [20] Question: Will the stabilization period be more in the first half of the year? - Management believes Q1 may have been the low point for the fiscal year, with expectations for gradual revenue growth [24] Question: Any color on Q2 revenue compared to last year? - Management refrained from providing specific guidance but anticipates revenue will increase on a quarterly basis [28]

Core Insights - California is experiencing a pharmaceutical renaissance, driven by significant investments from major biopharma companies like Amgen and Gilead, focusing on science, supply chains, and innovative therapies [1][4]. Group 1: Amgen's Investment - Amgen has invested $600 million to establish a state-of-the-art science and innovation center at its headquarters in Thousand Oaks, CA, aimed at enhancing collaboration among scientists, engineers, and researchers [2]. - This investment is part of Amgen's broader strategy, which has seen the company allocate over $40 billion into domestic manufacturing and R&D since the 2017 Tax Cuts and Jobs Act, including more than $5 billion in direct capital expenditures [3]. Group 2: Gilead's Development Initiatives - Gilead Sciences has initiated the construction of a new Technical Development Hub to accelerate biopharma innovation in the U.S., highlighting the importance of specialized infrastructure in the industry [4]. Group 3: Supply Chain Modernization - The investments from these companies also contribute to the modernization of supply chains, which are now viewed as critical systems requiring transparency, flexibility, and resilience [5]. - Advanced cold chain management practices are being developed, utilizing predictive analytics to monitor not only temperature but also equipment functionality, which is essential for therapeutic delivery [6]. Group 4: California's Biopharma Ecosystem - The current investments reflect California's reassertion as a national life sciences engine, fostering partnerships between academia and startups through its R&D hubs [8].

Summary of Royalty Pharma Investor Day Company Overview - **Company**: Royalty Pharma (NasdaqGS:RPRX) - **Industry**: Biopharma royalty market - **Event Date**: September 11, 2025 - **Key Leadership**: George Brofic (Investor Relations), Pablo (CEO), Ashwin (EVP), Chris (EVP), Marshall, Brienne, Terry Core Messages and Financial Performance - **Execution of Strategy**: Royalty Pharma has successfully executed its strategy since its IPO in 2020, delivering strong growth and returns in the rapidly expanding royalty market [21][23][24] - **Market Growth**: The biopharma royalty market has more than doubled in size since 2020, with expectations for continued growth driven by increasing capital needs in the biopharma sector [24][34] - **Financial Targets**: The company is on track to achieve a compounded annual growth rate (CAGR) of 12% in top line revenue since 2020, with a target of at least $4.7 billion by 2030 [26][28][59] - **Capital Deployment**: Royalty Pharma has deployed approximately $14 billion in capital on new royalty transactions since 2020, generating a 15% return on invested capital [26][29] Competitive Advantages - **Business Model**: Royalty Pharma has refined its business model over nearly 30 years, positioning itself as the optimized buyer of royalties, with a focus on delivering win-win solutions for partners [24][39] - **Investment Approach**: The company employs a rigorous investment process, historically transacting on only 2% of initial reviews, and maintains a healthy balance between approved and development stage investments [42][44] - **Risk Mitigation**: Royalty Pharma focuses on low-risk opportunities, with 90% of its royalty investments since 2020 projected to exceed its cost of capital [43][46] Industry Dynamics - **Funding Role of Royalties**: Royalties are increasingly recognized as a critical funding source for biopharma, offering flexibility and non-dilutive capital compared to traditional debt and equity [30][31] - **Market Demand**: The total addressable market for funding in biopharma is projected to exceed $1 trillion over the next decade, driven by high capital needs and the increasing number of licensing deals [34][88] - **Megatrends**: Key trends include rapid scientific innovation, R&D fragmentation, and significant capital requirements in the biopharma sector, all contributing to the growth of the royalty market [82][84][88] Survey Insights - **Deloitte Study**: A recent survey by Deloitte indicates that 87% of biotech executives would consider using royalties for financing, highlighting the growing acceptance and strategic importance of royalties in the capital structure [67][71] - **Executive Perspectives**: The survey revealed that two-thirds of executives cited the lack of equity dilution as a key benefit of royalties, with many expressing increased interest in royalty financing over the past three years [68][71] Philanthropic Efforts - **Community Engagement**: Royalty Pharma emphasizes its commitment to philanthropy and public service, supporting health equity, STEM education, and community initiatives [63][64] Conclusion - **Future Outlook**: Royalty Pharma is positioned for strong value creation, with a best-in-class investment platform and a commitment to delivering mid-teens annualized total shareholder returns over the next five years [60][63]

Group 1 - The presentation features Johnson & Johnson, with key executives including Chairman and CEO Joaquin Duato and Executive Vice President John Reed [1] - Terence Flynn, Morgan Stanley's U.S. biopharma analyst, is hosting the event [1]